ONCONasdaqPharmaceutical PreparationsFiscal year ends December 31
Onconetix, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.43−0.05 (-10.13%)
Close on Oct 19, 2026
- Market cap
- $965.06K
- P/E (TTM)
- –
- Dividend yield
- –
Onconetix, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| License [Member] | $600.00K | – | – | – | 73.6% | – |
| Other revenue [Member] | $587.88K | – | – | – | 72.1% | – |
| Product Sales [Member] | $225.84K | $249.03K | – | – | 27.7% | -9.3% |
| Development services [Member] | $1.65K | $2.28M | – | – | 0.2% | -99.9% |
| Development Services [Member] | – | $2.28M | $58.47K | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| Switzerland | $796.59K | $2.44M | $58.47K | – | 97.7% | -67.3% |
| European Union [Member] | $796.59K | $2.44M | $58.47K | – | 97.7% | -67.3% |
| Non-European Union (UK) [Member] | $18.78K | $23.84K | – | – | 2.3% | -21.2% |
| United Kingdom | $18.78K | $23.84K | – | – | 2.3% | -21.2% |
| United States | – | $63.12K | – | – | – | – |
From the segment and revenue-disaggregation notes of Onconetix's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.